药物涂层球囊联合准分子激光斑块消蚀术处理下肢动脉硬化闭塞症的临床研究#br#

中国医药导刊 ›› 2023, Vol. 25 ›› Issue (10): 1040-1044.

药物涂层球囊联合准分子激光斑块消蚀术处理下肢动脉硬化闭塞症的临床研究#br#

张超1，冯建宇1，王华1，樊朋程1，张延军1，曹敏1，赵亮2*

1.西安高新医院心脏大血管外科，陕西西安 710077；
2.西安交通大学第一附属医院东院血管外科，陕西西安 710089

收稿日期:2023-06-05 修回日期:2023-11-20 出版日期:2023-10-28 发布日期:2023-10-28

Clinical Study on the Treatment of Lower Extremity Arteriosclerosis Obliterans by Drug-Coated Balloon Combined with Excimer Laser Atherectomy#br#

1.Department of Cardiac and Major Vascular Surgery， Xi′an Gaoxin Hospital， Shaanxi Xi′an 710077， China；
2.Vascular Surgery Department， East District of the First Affiliated Hospital of Xi′an Jiaotong University， Shaanxi Xi′an 710089， China

Received:2023-06-05 Revised:2023-11-20 Online:2023-10-28 Published:2023-10-28

摘要/Abstract

摘要： 目的：探讨药物涂层球囊（DCB）联合准分子激光斑块消蚀术（ELA）处理下肢动脉硬化闭塞症（LEASO）的临床疗效。方法：以2018年4月至2022年4月我院收治的84例LEASO患者为研究对象，按随机数字表法分为DCB组、DCB+ELA组，每组各42例。DCB组行DCB治疗，DCB+ELA组应用ELA联合DCB治疗，进行为期1年的随访，比较两组患者的临床指标、术中及术后并发症发生情况、预后。结果：与术前（T0时点）比较，术后6个月（T1时点）时两组患者踝肱指数（ABI）及靶血管最小管腔直径（MLD）均有提高，且DCB+ELA组患者T1时点ABI及MLD均高于DCB组，而T1时点DCB+ELA组患者靶血管晚期管腔丢失（LLL）低于DCB组（P＜0.05）。两组患者术中及术后并发症发生情况比较，差异均无统计学意义（P＞0.05）。术后随访1年，两组患者靶血管血运重建率、无截肢生存率及病死率比较，差异均无统计学意义（P＞0.05），DCB+ELA组再狭窄率为7.14%，低于DCB组的26.19%（P＜0.05）。结论：DCB联合ELA处理LEASO可获确切临床效果，术中及术后并发症发生率较低，且预后良好。

关键词: 下肢动脉硬化闭塞症, 药物涂层球囊, 准分子激光斑块消蚀术

Abstract: Objective：To investigate the clinical efficacy of drug-coated balloon (DCB) combined with excimer laser atherectomy(ELA) in the treatment of lower extremity arteriosclerosis obliterans (LEASO). Methods：84 LEASO patients admitted to our hospital from April 2018 to April 2022 were selected and randomly divided into the DCB group (n=42 cases) and the DCB+ELA group (n=42 cases). 1-year follow-up was conducted to compare the clinical indicators， incidence of intraoperative and postoperative complications， and prognosis of the two groups of patients. Results：Compared with preoperative T0 time point， the ankle-brachial index (ABI) and target vessel minimum luminal diameter (MLD)of patients in both groups increased at the sixth month after surgery (T1 time point). At T1 time point，the ABI and MLD of patients in the DCB+ELA group were higher than those of the DCB group and the late lumen loss (LLL) of target vessel of patients in the DCB+ELA group was lower than that of DCB group (P<0.05). There was no statistical difference in the incidence of intraoperative and postoperative complications between the two groups (P>0.05). After 1 year follow-up， there was no statistical difference in the rates of target vessel revascularization， survival without amputation and mortality between the two groups (P>0.05). The restenosis rate in the DCB+ELA group was 7.14%， which was lower than than that of the DCB group (26.19%) (P<0.05). Conclusion：DCB combined with ELA in the treatment of LEASO can achieve definite clinical effect， with low incidence of intraoperative and postoperative complications and good prognosis.

Key words: Lower extremity arteriosclerosis obliterans, Drug-coated balloon, Excimer laser atherectomy

中图分类号:

R654.4

张超, 冯建宇, 王华, 樊朋程, 张延军, 曹敏, 赵亮. 药物涂层球囊联合准分子激光斑块消蚀术处理下肢动脉硬化闭塞症的临床研究#br#[J]. 中国医药导刊, 2023, 25(10): 1040-1044.

ZHANG Chao, FENG Jianyu, WANG Hua, FAN Pengcheng, ZHANG Yanjun, CAO Min, ZHAO Liang. Clinical Study on the Treatment of Lower Extremity Arteriosclerosis Obliterans by Drug-Coated Balloon Combined with Excimer Laser Atherectomy#br#[J]. CHINESE JOURNAL OF MEDICINAL GUIDE, 2023, 25(10): 1040-1044.

参考文献

[1]Aday AW， Matsushita K. Epidemiology of peripheral artery disease and polyvascular disease[J]. Circ Res， 2021，128(12)：1818-1832.
[2]谈洪统，李威，郭欢庆，等. 药物涂层球囊PTA治疗下肢动脉硬化闭塞症[J]. 中国介入影像与治疗学，2019，16(12)：709-712.
[3]蒋小浪，董智慧，符伟国. 准分子激光消蚀在下肢动脉硬化闭塞症治疗中的应用及前景[J]. 中华外科杂志，2022，60(12)：1041-1044.
[4]Zheng YH， Song XT. Progress and prospect of the treatment of lower extremity arteriosclerosis obliterans[J].Chinese Journal of Surgery， 2021，59(12)：961-964.
[5]Giannopoulos S， Jeon-Slaughter H， Kahlon RS， et al. Comparative 12-month outcomes of drug-coated balloon versus non-drug-coated balloon revascularization strategy in chronic limb-threatening ischemia： results from the XLPAD registry[J]. Cardiovasc Revasc Med， 2020，21(10)：1276-1284.
[6]李杨，谷涌泉，郭连瑞，等. 准分子激光消蚀辅助普通球囊扩张治疗膝下动脉病变临床研究[J]. 介入放射学杂志，2020，29(1)：30-34.
[7]Bürckenmeyer F， Aschenbach R， Diamantis I， et al. Excimer laser atherectomy in complex peripheral artery disease： a prospective European registry[J]. J Cardiovasc Surg (Torino)， 2021，62(2)：153-161.
[8]乔冠宇，蒋小浪，陈斌，等. 血管内超声在准分子激光消蚀联合药物涂层球囊治疗下肢动脉硬化闭塞症中的应用价值[J]. 中华外科杂志，2023，61(2)：150-155.
[9]He Z， Wang H， Lin F， et al. The safety and efficacy of different endovascular treatments for in-stent restenosis of the femoropopliteal artery： a network meta-analysis[J]. Vasc Med， 2022，27(3)：239-250.
[10]Su Z， Li Y， Yang S， et al. Excimer laser atherectomy combined with drug-coated balloon angioplasty for the treatment of femoropopliteal arteriosclerosis obliterans[J]. Ann R Coll Surg Engl， 2022，104(9)：667-672.
[11]中华医学会外科学分会血管外科学组. 下肢动脉硬化闭塞症诊治指南[J]. 中国血管外科杂志（电子版），2015，7(3)：145-151.
[12]张恺欣，张明，陈军，等. 药物涂层球囊扩张与经皮腔内球囊扩张合并支架植入术对下肢动脉硬化闭塞病变患者治疗的各项临床指标的影响[J]. 河北医学，2022，28(6)：960-964.
[13]谷涌泉，郭连瑞，齐立行，等. 准分子激光消蚀联合药物涂层球囊治疗下肢动脉硬化闭塞20例[J]. 介入放射学杂志，2018，27(8)：779-782.
[14]武辉林，李坤. 准分子激光消蚀术治疗下肢动脉硬化疾病的研究进展[J]. 中华血管外科杂志，2022，7(3)：217-220.
[15]蒋小浪，鞠帅，陈斌，等. 减容手术治疗下肢动脉疾病101例效果分析[J]. 中华外科杂志，2021，59(12)：969-974.
[16]Cantu D， Jawaid O， Kokkinidis D， et al. Outcomes of drug-coated balloon angioplasty vs. conventional balloon angioplasty for endovascular treatment of common femoral artery atherosclerotic disease[J]. Cardiovasc Revasc Med， 2020 ，21(7)：867-874.
[17]Shammas NW， Shammas GA， Jones-Miller S， et al. Long-term outcomes with Jetstream atherectomy with or without drug coated balloons in treating femoropopliteal arteries： a single center experience (JET-SCE)[J]. Cardiovasc Revasc Med， 2018 ，19(7)：771-777.
[18]Reijnen MMPJ， van Wijck I， Zeller T， et al. Outcomes after drug-coated balloon treatment of femoropopliteal lesions in patients with critical limb ischemia： a post hoc analysis from the IN.PACT global study[J]. J Endovasc Ther， 2019 ，26(3)：305-315.
[19]Torsello G， Stavroulakis K， Brodmann M，et al. Three-year sustained clinical efficacy of drug-coated balloon angioplasty in a real-world femoropopliteal cohort[J]. J Endovasc Ther， 2020，27(5)：693-705.
[20]Dippel EJ， Makam P， Kovach R， et al. Randomized controlled study of excimer laser atherectomy for treatment of femoropopliteal in-stent restenosis： initial results from the EXCITE ISR trial (EXCImer Laser Randomized Controlled Study for Treatment of FemoropopliTEal In-Stent Restenosis)[J]. JACC Cardiovasc Interv， 2015 ，8(1)：92-101.
[21]王鹏，陈晓伟，包晗，等. 药物涂层球囊与金属裸支架治疗下肢动脉硬化闭塞症效果和安全性对比[J]. 介入放射学杂志，2019，28(12)：1176-1180.
[22]Kokkinidis DG， Behan S， Jawaid O， et al. Laser atherectomy and drug-coated balloons for the treatment of femoropopliteal in-stent restenosis： 2-year outcomes[J]. Catheter Cardiovasc Interv， 2020，95(3)：439-446.
[23]Jiang XL， Ju S， Chen B， et al. Application and value of excimer laser ablation in the treatment of lower limb atherosclerotic obliterans[J].National Medical Journal of China， 2021，101(14)：1026-1030.
[24]Kokkinidis DG， Hossain P， Jawaid O， et al. Laser atherectomy combined with drug-coated balloon angioplasty is associated with improved 1-year outcomes for treatment of femoropopliteal in-stent restenosis[J]. J Endovasc Ther， 2018 ，25(1)：81-88.
[25]王毅，郑江华，程鹏，等. 紫杉醇药涂球囊扩张成形术联合金属裸支架置入术治疗下肢动脉硬化闭塞症的临床疗效及安全性[J]. 山东医药，2023，63(3)：58-61.
[26]庄金满，李天润，李选，等. 机械减容技术在下肢动脉硬化闭塞性病变中的应用[J]. 中华外科杂志，2022，60(8)：762-766.
[27]陶源，余朝文. 药物涂层球囊联合Turbohawk减容治疗下肢动脉硬化闭塞病变的效果分析[J]. 临床外科杂志，2021，29(5)：470-473.

快速检索引用检索图表检索高级检索